Intercept Pharmaceuticals (ICPT) Outperform, $493 PT Reiterated at Wedbush
Tweet Send to a Friend
Wedbush analyst Liana Moussatos reiterated an Outperform rating and $493 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) saying the recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


